These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 12036921)

  • 21. A novel methionine aminopeptidase-2 inhibitor, PPI-2458, inhibits non-Hodgkin's lymphoma cell proliferation in vitro and in vivo.
    Cooper AC; Karp RM; Clark EJ; Taghizadeh NR; Hoyt JG; Labenski MT; Murray MJ; Hannig G; Westlin WF; Thompson CD
    Clin Cancer Res; 2006 Apr; 12(8):2583-90. PubMed ID: 16638869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-CD7 antibody and immunotoxin treatment of human CD7(+)T-cell leukaemia is significantly less effective in NOD/LtSz-scid mice than in CB.17 scid mice.
    Flavell DJ; Warnes SL; Noss AL; Flavell SU
    Br J Cancer; 2000 Dec; 83(12):1755-61. PubMed ID: 11104577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells.
    Schabath H; Runz S; Joumaa S; Altevogt P
    J Cell Sci; 2006 Jan; 119(Pt 2):314-25. PubMed ID: 16390867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic manipulation of stromal cell-derived factor-1 attests the pivotal role of the autocrine SDF-1-CXCR4 pathway in the aggressiveness of breast cancer cells.
    Kang H; Mansel RE; Jiang WG
    Int J Oncol; 2005 May; 26(5):1429-34. PubMed ID: 15809737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1alpha (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK/ERK signaling pathway-dependent NF-kappaB activation.
    Kukreja P; Abdel-Mageed AB; Mondal D; Liu K; Agrawal KC
    Cancer Res; 2005 Nov; 65(21):9891-8. PubMed ID: 16267013
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CXCR4 enhances adhesion of B16 tumor cells to endothelial cells in vitro and in vivo via beta(1) integrin.
    Cardones AR; Murakami T; Hwang ST
    Cancer Res; 2003 Oct; 63(20):6751-7. PubMed ID: 14583470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
    Lopes de Menezes DE; Denis-Mize K; Tang Y; Ye H; Kunich JC; Garrett EN; Peng J; Cousens LS; Gelb AB; Heise C; Wilson SE; Jallal B; Aukerman SL
    J Immunother; 2007 Jan; 30(1):64-74. PubMed ID: 17198084
    [TBL] [Abstract][Full Text] [Related]  

  • 28. S1P(1) overexpression stimulates S1P-dependent chemotaxis of human CD34+ hematopoietic progenitor cells but strongly inhibits SDF-1/CXCR4-dependent migration and in vivo homing.
    Ryser MF; Ugarte F; Lehmann R; Bornhäuser M; Brenner S
    Mol Immunol; 2008 Nov; 46(1):166-71. PubMed ID: 18760838
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemokine receptor CXCR4-dependent internalization and resecretion of functional chemokine SDF-1 by bone marrow endothelial and stromal cells.
    Dar A; Goichberg P; Shinder V; Kalinkovich A; Kollet O; Netzer N; Margalit R; Zsak M; Nagler A; Hardan I; Resnick I; Rot A; Lapidot T
    Nat Immunol; 2005 Oct; 6(10):1038-46. PubMed ID: 16170318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells.
    Burger M; Glodek A; Hartmann T; Schmitt-Gräff A; Silberstein LE; Fujii N; Kipps TJ; Burger JA
    Oncogene; 2003 Nov; 22(50):8093-101. PubMed ID: 14603250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effects of anti-CXCR4 monoclonal antibody on adhesion and proliferation of human acute myelocytic leukemia cell line HL-60].
    Wei L; Kong PY; Chen XH; Peng XG; Zeng DF; Chang C; Yang WB; Liu H; Liu L; Wang QY; Zhang Y
    Ai Zheng; 2004 Nov; 23(11):1273-7. PubMed ID: 15522172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The role of stromal cell-derived factor and its receptor-CXCR4 in G-CSF-induced hematopoietic stem cell mobilization].
    Jin FY; Qiu LG; Li QC; Meng HX; Wang YF; Yu Z; Li Q; Han JL
    Zhonghua Xue Ye Xue Za Zhi; 2007 Feb; 28(2):98-102. PubMed ID: 17650669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination immunotherapy of B-cell non-Hodgkin's lymphoma with rituximab and interleukin-2: a preclinical and phase I study.
    Eisenbeis CF; Grainger A; Fischer B; Baiocchi RA; Carrodeguas L; Roychowdhury S; Chen L; Banks AL; Davis T; Young D; Kelbick N; Stephens J; Byrd JC; Grever MR; Caligiuri MA; Porcu P
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6101-10. PubMed ID: 15447996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interaction with human stromal cells enhances CXCR4 expression and engraftment of cord blood Lin(-)CD34(-) cells.
    Kobune M; Kawano Y; Takahashi S; Takada K; Murase K; Iyama S; Sato T; Takimoto R; Niitsu Y; Kato J
    Exp Hematol; 2008 Sep; 36(9):1121-31. PubMed ID: 18562079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer.
    Dewan MZ; Ahmed S; Iwasaki Y; Ohba K; Toi M; Yamamoto N
    Biomed Pharmacother; 2006 Jul; 60(6):273-6. PubMed ID: 16828253
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stromal cell-derived factor-1/CXCR4 enhanced motility of human osteosarcoma cells involves MEK1/2, ERK and NF-kappaB-dependent pathways.
    Huang CY; Lee CY; Chen MY; Yang WH; Chen YH; Chang CH; Hsu HC; Fong YC; Tang CH
    J Cell Physiol; 2009 Oct; 221(1):204-12. PubMed ID: 19496172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of stromal-derived factor-1 in the hematopoietic-supporting activity of human mesenchymal stem cells.
    Van Overstraeten-Schlögel N; Beguin Y; Gothot A
    Eur J Haematol; 2006 Jun; 76(6):488-93. PubMed ID: 16494621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.
    Wahl AF; Klussman K; Thompson JD; Chen JH; Francisco LV; Risdon G; Chace DF; Siegall CB; Francisco JA
    Cancer Res; 2002 Jul; 62(13):3736-42. PubMed ID: 12097283
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma.
    DiJoseph JF; Dougher MM; Kalyandrug LB; Armellino DC; Boghaert ER; Hamann PR; Moran JK; Damle NK
    Clin Cancer Res; 2006 Jan; 12(1):242-9. PubMed ID: 16397048
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases.
    Zeelenberg IS; Ruuls-Van Stalle L; Roos E
    Cancer Res; 2003 Jul; 63(13):3833-9. PubMed ID: 12839981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.